The study showed that pembrolizumab plus chemotherapy was superior to placebo plus chemotherapy for OS and PFS patients with esophageal SCC and PD-L1 CPS of 10 or more [19]. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.